Floatz logo

DEXAMETHASONE

Transplant Ineligible

Massachusetts General HospitalSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

7 Active assets in the Transplant Ineligible cohort.

Asset / SponsorPhaseRating
DARATUMUMAB
Massachusetts General Hospital
Phase 2CCC
Hyaluronidase fihj
Massachusetts General Hospital
Phase 2CCC
Elranatamab
Massachusetts General Hospital
Phase 2CCC
Bortezomib
Massachusetts General Hospital
Phase 2CCC
cc-5013
Massachusetts General Hospital
Phase 2CCC
FILGRASTIM
iOMEDICO AG
D
CIS-DIAMMINEDICHLOROPLATINUM II
iOMEDICO AG
D

Same molecule, other indications

DEXAMETHASONE is also rated in:

chemotherapy-induced toxicityDormant
A
Indicative ·
82 / 100
View asset →
adult acute lymphoblastic leukemiaDormant
BBB
Indicative ·
79 / 100
View asset →
B-cell childhood acute lymphoblastic leukemiaDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →